A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1403 in Participants With Type 2 Diabetes Mellitus
Latest Information Update: 25 Jan 2026
At a glance
- Drugs MK 1403 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 14 Jan 2026 Status changed from not yet recruiting to recruiting.
- 01 Dec 2025 New trial record